ClinicalTrials.gg
Active, not recruitingNCT06127836Updated Nov 6, 2026

Study of Near-Infrared Imaging With Indocyanine Green for Detection of Sentinel Lymph Nodes in People With Vulvar Cancer

An interventional study of ICG guided sentinel lymph node biopsy in Vulvar Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Active, not recruiting at 8 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Memorial Sloan Kettering Cancer Center · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Vulvar Neoplasms with a site in United States — 19 open to participants now, 29 under way, none of them phase 3. Vulvar Neoplasms · United States.

Enrollment
59th of 80
22 · median 46
Started
2023
with 6 others
No phase
32 of 107
4 open now
Primary completion
2027-11
later than 16 of 28 live
Registered
93rd of 107
by date
Lead sponsor
4 of 107
Memorial Sloan Kettering Cancer Center

Among the 107 studies in Vulvar Neoplasms with a site in United States, this one is the 59th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2023, is one of 32 with no phase, reaches primary completion later than 16 of the 28 other live ones, and was the 93rd registered.

Vulvar Neoplasms

236 studies on the registry are indexed under Vulvar Neoplasms; 69 are open to participants now.

Browse Vulvar Neoplasms studies →

Open to participants now

19 of the 107 studies in Vulvar Neoplasms with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 53 Vulvar Neoplasms studies recruiting now, 39 (74%) set no upper age limit and 7 (13%) stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Vulvar Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare two types of imaging for sentinel lymph node (SLN) mapping in people with early-stage vulvar cancer. The researchers will compare indocyanine green near-infrared (ICG-NIR) imaging with lymphoscintigraphy. All participants in this study will be scheduled for standard surgical treatment at Memorial Sloan Kettering Cancer Center (MSK). This surgical treatment includes SLN mapping (with both lymphoscintigraphy and ICG-NIR imaging) and SLN biopsy.

03

Conditions studied

  • Vulvar Cancer

Browse trials for

Keywords

  • Near-Infrared Imaging
  • Indocyanine Green
  • Sentinel Lymph Nodes
  • 23-310
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • Newly diagnosed with vulvar cancer and scheduled to undergo SLN (patients with squamous cell carcinomas and melanomas will be included)
  • Primary tumor ≤4 cm in size
  • For patients with squamous cell carcinoma, >1 mm of invasion is required

Exclusion criteria

Exclusion Criteria:

  • Clinically or radiographically enlarged inguinofemoral lymph nodes (if imaging is performed)
  • Presence of distant
  • Absolute to radiocolloid Tc-99 or ICG
  • Nonsquamous or nonmelanoma histologic subtype
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    patients undergoing preoperative lymphoscintigraphy

    Patients will undergo radiocolloid lymphoscintigraphy before their surgery; the surgeon will be blinded to the results of this procedure. The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only.

    Procedure: ICG guided sentinel lymph node biopsy

Interventions

  • ProcedureICG guided sentinel lymph node biopsy

    The surgeon will subsequently inject ICG in accordance with the SLN protocol in the operating room and will identify and remove the SLN by use of near-infrared imaging guidance only. Once the surgeon has identified the SLN in this way, he or she will be unblinded to the results of the lymphoscintigraphy and will use the results of preoperative imaging and an intraoperative gamma counter to confirm the SLNs.

06

What researchers measure

Primary outcomes

  1. success of identifying the SLN

    by use of near-infrared imaging with ICG injection. Patients will be eligible for assessment if they undergo attempted SLN mapping by lymphoscintigraphy and near-infrared imaging with ICG injection. The primary endpoint is the accurate identification of the SLN, defined as the uptake of ICG in the proximalmost draining lymph node in the inguinofemoral chain. Evaluate the ability of near-infrared imaging with ICG injection to detect the inguinofemoral SLN in patients with early-stage vulvar cancer, compared with radiocolloid lymphoscintigraphy, the current standard.

    Time frame: 18 months

07

Study locations

8 sites
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Of 43 non-industry interventional studies with no phase under Vulvar Neoplasms, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 129. This study's planned 48 months is above that.

Counting every sponsor, half of 43 studies reached it within 28 months; a quarter within 17 and three quarters within 129.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Nov 2026 → Nov 2027 and completion Nov 2026 → Nov 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2023
First posted
Nov 13, 2023
StartActual
Nov 6, 2023
Primary completionEst.
Nov 2027was Nov 2026
CompletionEst.
Nov 2027was Nov 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 2026→Nov 2027
Nov 6, 2026
Study completion
Nov 2026→Nov 2027
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Primary completion Nov 2026→Nov 2027
    Study completion Nov 2026→Nov 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06127836
Responsible party
Sponsor
First posted
Nov 13, 2023
Start date
Nov 6, 2023
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Vance Broach, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion